Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.
Approval Alert | Lisocabtagene Maraleucel in Relapsed/Refractory Mantle Cell Lymphoma
Findings from the TRANSCEND NHL 001 trial support the FDA approval of lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
2
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
3
Episode 16: Anticipated ESMO 2025 Data That May Change GU Oncology
4
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
5
